ADAPY Adaptimmune Therapeutics PLC
Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1621227 · Fiscal year ends 12/31
Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-54.0%
TTM net income YoY-134.1%
TTM EPS YoY-83.3%
Revenue 3-yr CAGR77.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-252.3%
Net margin-260.8%
FCF margin-294.5%
EBITDA margin-237.0%
Returns
ROE-1,341.1%
ROA-75.1%
ROIC (approx.)—
Asset turnover0.29x
Leverage & solvency
Liabilities / assets154.3%
Debt / equity—
Current ratio1.52x
Interest coverage-28.99x
Cash quality & payout
Operating cash flow / net income1.12x
Accruals ratio9.0%
Payout ratio—
Capex / revenue2.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $178.03M | $60.28M |
| Cost of revenue | $70,000 | — |
| Gross profit | $177.96M | — |
| R&D expense | $149.06M | $126.51M |
| SG&A expense | $87.26M | $73.51M |
| Operating income | -$68.76M | -$139.74M |
| Interest expense | $3.35M | — |
| Pretax income | -$67.24M | -$112.53M |
| Income tax | $3.58M | $1.34M |
| Net income | -$70.81M | -$113.87M |
| EBITDA | -$57.95M | -$130.29M |
| EPS (basic) | -0.05 | -0.09 |
| EPS (diluted) | -0.05 | -0.09 |
| Weighted avg. shares (diluted) | 1.51B | 1.21B |
| Balance sheet | ||
| Cash & equivalents | $91.14M | $147.02M |
| Short-term investments | $60.47M | $2.95M |
| Receivables | $1.45M | $821,000 |
| Inventory | $7.32M | — |
| Current assets | $188.17M | $207.55M |
| PP&E, net | $31.31M | $50.95M |
| Intangibles | $3.88M | $330,000 |
| Total assets | $245.96M | $282.62M |
| Current liabilities | $64.53M | $72.79M |
| Long-term debt | $50.24M | — |
| Total debt | $50.24M | — |
| Total liabilities | $234.11M | $243.10M |
| Shareholders' equity | $11.85M | $39.51M |
| Net debt | -$40.90M | — |
| Shares outstanding | 1.54B | 1.36B |
| Cash flow statement | ||
| Operating cash flow | -$73.21M | -$140.88M |
| Capital expenditure | $886,000 | $4.68M |
| Free cash flow | -$74.09M | -$145.56M |
| Investing cash flow | -$58.95M | $176.54M |
| Financing cash flow | $78.75M | $880,000 |
| Depreciation & amortization | $10.81M | $9.45M |
| Stock-based compensation | $12.05M | $11.77M |
Free plan shows the latest 2 periods; Pro shows all 11 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.